

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

ANTIBACTERIAL EFFECTS OF METHANOL EXTRACT OF *Bryophyllum pinnatum* L ON METHICILLIN RESISTANT *Staphylococcus aureus* (MRSA) ISOLATED FROM URINE

ABSTRACT

There are major concerns about rising levels of methicillin resistant *Staphylococcus aureus* (MRSA). This is due to the difficulties in treating the infections which they cause and the ease with which they spread in hospitals. This has necessitated the continuous search for alternative anti-MRSA agents. Efforts in this study was therefore directed at isolation of MRSA from the urine of patients and its susceptibility to the methanol extract and aqueous fraction of *Bryophyllum pinnatum* . Urine samples from the urine of patients were screened for the presence of *Staphylococcus aureus* using conventional microbiological methods. Confirmed isolates were screened for methicillin resistance by confirming their susceptibility or otherwise to 30µg cefoxitin. Detection of Mec A gene by Polymerase chain reaction (PCR) was further used to confirm some MRSA isolates. Conventional susceptibility testing methods were used to compare the activity of both methanol extract of *Brophyllum pinnatum* and its aqueous fraction on the MRSA isolates. Results obtained confirmed the susceptibility of the MRSA isolates to the extracts and that their activity was time dependent. It also showed that the extract was only moderately toxic with an LD₅₀ of 866.03mg/kg body weight and that at the MIC and 2xMIC their activity was only bacteriostatic. Results obtained are intended to be used to prove that in the search for alternative anti- MRSA agents from natural sources, *Bryophyllum pinnatum* will be a possible candidate for further investigation.

Keywords: Methicillin; *Bryophyllum pinnatum*; Bacteriostatic; Susceptible; Alternative

INTRODUCTION

Staphylococcus aureus is a facultative anaerobic, Gram positive cocci. It is found as part of normal skin flora, in the nostrils [1] and as a normal inhabitant of lower reproductive tract of women [2]. *Staphylococcus aureus* is a versatile human pathogen that causes diseases ranging from relatively mild infections of skin and soft tissue to life-threatening sepsis in humans. It is also known to cause cause both hospital and community-associated infections. These infections occur as a result of a breach in the mucosal barriers of the body. It also takes advantage of suppressed inert and active immunity of an individual to cause infections [3].

41 *Staphylococcus aureus* quickly develops resistance and is capable of producing many resistant
42 strains [3]. It can acquire resistance genes through horizontal gene transfer mechanisms which
43 enable them to show resistance against antimicrobial agents and spread worldwide [4]. Presently,
44 a large percentage of the infections caused by *Staphylococcus aureus* are due to methicillin-
45 resistant strains of *Staphylococcus aureus*.

46 Methicillin resistant *Staphylococcus aureus* (MRSA) is a specific strain of the *Staphylococcus*
47 *aureus*, which is resistant to methicillin and all β -lactams [5]. It has been associated with many
48 infection sites including bones and joints, lungs, and the urinary tract. It also causes bacteremia
49 which possibly leads to endocarditis osteomyelitis [6]. MRSA is associated with high morbidity
50 and mortality rates because of the development of multidrug antibiotic resistance [7]. Resistance
51 to methicillin is due to the presence of *mecA* gene, which is a part of a large cluster called
52 staphylococcal cluster cassette chromosome *mec* (SCC*mec*) [8]. The *mecA* gene encodes an
53 altered penicillin binding protein 2a having reduced affinity for β -lactams thereby providing
54 resistance to practically all β -lactams antibiotics [9].

55 *Bryophyllum pinnatum* (Lam.) Kurz (Crassulaceae) also known as Ndodob or Afiayo among the
56 Ibibio people of southern Nigeria, is a perennial herb growing widely and used in folkloric
57 medicine in tropical Africa, tropical America, India, China and Australia. A number of its specie
58 are cultivated as ornamentals and are popular tropical house plants. It is popularly known as
59 miracle plant or life plant.

60 *B. pinnatum* is used in ethno medicine generally for the treatment of ear ache, cough, diarrhea,
61 dysentery, abscesses, ulcer, insect bites, heart-troubles, epilepsy, arthritis, dysmenorrhea and
62 whitlow [9] also reported the use of the leaves and leaf juice traditionally as anti-inflammatory,
63 antipyretic, antimicrobial antioxidant, antitumor, antidiabetic, antiulcer, antiseptic,
64 hypocholesterolemic and cough suppressant. Results presented in this work shows the effects of
65 the plant *Bryophyllum pinnatum* on Methicillin resistant *Staphylococcus aureus* and the
66 possibility of its use in the control of infections caused by them.

67

68 **METHODOLOGY**

69 **Sample Collection**

70 Fresh urine samples were collected aseptically in sterile urine bottles from patients with the help
71 of the laboratory staff at the University of Uyo Teaching hospital. All samples collected were
72 properly labelled and taken to the pharmaceutical microbiology laboratory, Faculty of Pharmacy,
73 University of Uyo for further examinations.

74 ***Staphylococcus aureus* Isolation and Identification.**

75 Mannitol salt agar was prepared according to the manufacturers' instruction, sterilized and
76 allowed to cool to 45°C. It was then poured into a sterile petri dish and allowed to solidify. A
77 loopful of each specimen was inoculated using streak method on the surface of the already
78 solidified mannitol salt agar and incubated at 37°C for 24 hours. The discrete colonies were

79 isolated and further subcultured using mannitol salt to obtain a pure culture. Morphological
80 characteristics of *Staphylococcus aureus* on mannitol salt agar were used to differentiate
81 *Staphylococcus aureus* from other microorganisms. Identified *Staphylococcus aureus* were Gram
82 stained and viewed under the microscope to further confirm them. Catalase and coagulase tests
83 as described by [10] were further employed to confirm the presumptive isolates to be
84 *Staphylococcus aureus*.

85 **Identification of MRSA**

86 Isolates subjected to cefoxitin disc diffusion testing using a 30µg cefoxitin **were** used. The results
87 obtained during the susceptibility tests were interpreted according to [11] guidelines for the
88 identification of those which are methicillin resistant. An inhibition zone diameter of ≤ 21 mm is
89 considered methicillin resistance while ≥ 22 mm is considered methicillin sensitive.

90 **Detection of mecA gene by PCR Technique**

91 Selected isolates found to be MRSA by specific phenotypic features were further confirmed by
92 the detection of the MecA gene using the Polymerase Chain Reaction(PCR) . The mecA-specific
93 primer pairs used are Forward, 5'- GTT GTA GTT GTC GGG TTT GG-3', and Reverse, 5'- CTT
94 CCA CAT ACC ATC TTC TTT AAC-3'. The extracted DNA cells were amplified beginning
95 with an initial denaturation step at 94°C for 5 min, followed by 33 cycles of amplification at
96 94°C for 30 sec, annealing at 47°C for 30 sec and extension at 72°C for 30 sec, followed by final
97 extension step at 72°C for 5 min. The amplified products were visualised by electrophoresis in
98 1.5% agarose gels stained with ethidium bromide.

99

100 **Plant Collection and Authentication**

101 The leaves of Bryophyllum pinnatum were obtained from the medicinal plant farm of the Faculty
102 of Pharmacy University Uyo Nigeria. They were authenticated using taxonomic keys provided
103 by the Department of Pharmacognosy, Faculty of Pharmacy, University of Uyo and a voucher
104 with specimen number UUPH27(a) is kept in the Faculty herbarium for further reference.

105 **Preparation and Extraction of Plant Samples**

106 The leaves were dried in an oven at 45°C, grinded and made into a fine powder using laboratory
107 mortar and pestle.

108 Methanol (70%) was poured into a container containing the dried leaves and allowed to macerate
109 for 72hours at room temperature with intermittent shaking. The extract was then filtered and
110 concentrated in a water bath at 40°C.

111 **Phytochemical Screening**

112 The leaf extract was screened for its phytochemical constituents using the methods
113 described by [12] and [13]

114 **Fractionation of Extract**

115 The methanol extract was fractionated using petroleum ether, chloroform and water according to
116 the method of [14]. 20g of dried extract was dissolved in 200ml of distilled water before shaking
117 vigorously in a separating flask. The mixture obtained was filtered using filter paper to remove
118 debris. Thereafter, 200 ml of petroleum ether was added to the mixture, shaken vigorously and
119 allowed to settle., the petroleum ether layer (on top) was removed and concentrated while a
120 further 200ml of chloroform was added to the aqueous layer and also shaken vigorously and
121 allowed to settle. The aqueous and the chloroform layers were further separated while the
122 chloroform portion was concentrated to dryness by allowing it to stand on the laboratory bench
123 until all the solvent evaporated. The aqueous layer was concentrated to dryness using mild heat
124 and the resulting fraction was stored in a desiccator until needed.

125

126 **Acute Toxicity Testing**

127 Lorke's method [15] was used to determine the lethal dose (LD₅₀) of the crude extract of
128 *Bryophyllum pinnatum* leaf that kills 50% of the test animal population. In the first phase, nine
129 healthy mice were divided into three groups of three animals each. The animals were fasted for
130 24 hours and each group of animals were administered different doses (2000, 3000 and 5000
131 mg/kg body weight) of the plant extract. The animals were placed under observation for 24 hours
132 and monitored for mortality. The second phase involved the use of six mice which were
133 distributed into two groups of three animals each. The animals were administered different doses
134 (1000 and 1500mg/kg body weight) of the plant extract. Then, the third phase involved twelve
135 mice which were distributed into four groups of three animals each. The animals were
136 administered different doses (250, 500, 750 and 1000mg/kg body weight) of the plant extract.
137 They will then be monitored for 24 hours and mortality taken note of. All experimental protocols
138 were in compliance with the Faculty of Pharmacy University of Uyo ethics on research in
139 animals as well as internationally accepted principles for laboratory animal use and care.

140 **Susceptibility Screening**

141 The agar cup diffusion method was used for this test. Mueller Hinton agar plates were prepared
142 according manufacturer's instructions and with a 4mm sterile cork borer, wells were bored at
143 equidistant after inoculation on each plate of a 24-hour overnight broth culture of the test
144 organisms. To each of the cups, 0.1ml each of different concentrations of the crude extract and
145 aqueous fraction ranging from 3.125 -100mg/ml made using sterile water were introduced. The
146 plates were allowed a pre-diffusion time of 1 hour at room temperature and then incubated at
147 37°C for 24 hours after which the zones of inhibition were read to the nearest millimeter.

148 **Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration**
149 **(MBC)**

150 The minimum inhibitory concentration of the crude methanol extract and aqueous fraction were
151 determined using the tube dilution method [16]. 1 ml of the extract solution at concentrations of
152 25 mg/ml was added to 1 ml of nutrient broth and was subsequently transferred thus: 1 ml from
153 the first tube to the next up to the sixth tube. Then, 1 ml of 24 hours culture of test organisms
154 was inoculated into each test tube and mixed thoroughly. The tubes were incubated for 24 hours
155 at 37°C and examined for turbidity as sign of growth. The tube with the lowest concentration of
156 extract with no detectable growth was considered the MIC. A loopful from each tube not
157 showing growth was plated out on nutrient agar and incubated at 37°C for 24 hours. The tube
158 with the lowest concentration that yielded no growth in the plate subculture was considered as
159 the MBC of the extract for each test bacteria isolate.

160

161 **Determination of Rate of Kill**

162 Four bottles labelled 1, 2, 3 and 4 were used for each isolate, where bottle 1 served as the
163 control. To each bottle, 9 ml of nutrient broth was added. To bottles 2, 3 and 4, the isolate (1 ml
164 of a standardised overnight culture) and an aliquot of the extract to achieve the MIC of the
165 organism was added. This process was repeated for each isolate being determined. The bottles
166 were then incubated at 37°C and viable counts taken at 30 min interval by withdrawing 0.1 ml of
167 the mixture in the bottle and diluting in normal saline containing 3% Tween 80. The diluted
168 mixtures were plated out on nutrient agar plates and incubated at 37°C for 24 hours. Developed
169 colonies were counted and the colony forming units (cfu/ml) calculated. The process was
170 repeated with an extract concentration of 2×MIC

171 **RESULTS**

172 **Sample collection and confirmation of *S. aureus***

173 Out of a total of 150 fresh urine samples screened, results obtained showed that 89 of the
174 samples were positive for *Staphylococcus aureus*

175 **Identification of MRSA**

176 Out of a total of 89 isolates of *S. Aureus*, 66 isolates were found to be resistant to cefoxitin
177 (30µg) confirming them as phenotypic MRSA (74%).

178

179

180

181 **Detection of *mecA* gene by PCR Technique**

182 Confirmation of MRSA for some selected isolates was performed by detection of *mecA* gene
183 using PCR assay. Out of the 8 selected isolates, results revealed that 7 carried *mecA* gene. The
184 PCR-amplified DNA products of this gene for the 8 selected isolates are shown in figure 1.

185

186

187


188

189

190

191

192



193 **Figure 1:** Amplicon of *mecA* gene : Lanes C7,B8,E9,B10,B12,D16 and A6 are tested isolates
194 with positively amplified *mecA* (indicated by 312 bp PCR amplicon). Lane 4 is *mecA* negative.

195

196

197

198

199

200

201

202 **Phytochemical Screening**

203 Results of Phytochemical screening showed the presence of a number of secondary metabolites
 204 including tannins, flavonoids and cardiac glycosides (Table 1).

205

206 Table 1: Phytochemical Screening of Methanol extract of *Bryophyllu pinnatum*

| Metabolites | Plant Extract |
|--------------------|---------------|
| Saponins | - |
| Alkaloids | - |
| Tannins | + |
| Flavonoids | + |
| Cardiac glycosides | + |
| Cardenolide | + |
| Steroids | + |

207 +=positive, - = negative

208 **Acute Toxicity Testing**

209 The result of the acute toxicity testing showing concentration of the crude methanol extract of *B.*
 210 *pinnatum* leaf that killed 50% of mice, expressed as LD₅₀ is presented in Table 2.

211 Table 2: Acute toxicity test of Methanol extract of *Brophyllum pinnatum*

| Phases | No. of mice | Weight of mice (g) | Dose (mg/kg) | Mortality | LD ₅₀ (mg/kg) |
|--------|-------------|--------------------|--------------|-----------|--|
| 1 | 3 | 20 | 2000 | 3/3 | $\sqrt{D_0 \times D_{100}}$ $\sqrt{750 \times 1000}$ =866.03 (mg/kg) |
| | | 22 | | | |
| | | 24 | | | |
| | 3 | 25 | 3000 | 3/3 | |
| | | 22 | | | |
| | | 23 | | | |
| | 3 | 22 | 5000 | 3/3 | |
| | | 23 | | | |
| | | 23 | | | |
| 2 | 3 | 20 | 1000 | 3/3 | |

| | | | | |
|---|---|----|------|-----|
| | | 21 | | |
| | | 23 | | |
| | 3 | 20 | 1500 | 3/3 |
| | | 22 | | |
| | | 21 | | |
| 3 | 3 | 21 | 250 | 0/3 |
| | | 22 | | |
| | | 22 | | |
| | 3 | 22 | 500 | 0/3 |
| | | 24 | | |
| | | 23 | | |
| | 3 | 22 | 750 | 0/3 |
| | | 21 | | |
| | | 20 | | |
| | 3 | 22 | 1000 | 3/3 |
| | | 22 | | |
| | | 21 | | |

212 D₀= highest dose without mortality, 750mg/kg body weight; D₁₀₀= lowest dose that produced
 213 mortality, 1000mg/kg body weight

214

215

216

217 **Susceptibility Screening**

218 Microbial susceptibility test with the crude methanol extract and aqueous fraction of *B. pinnatum*
 219 leaf showed zones of growth inhibitions whose diameters were measured in millimetres (mm)
 220 and are presented in Table 3.

221 Table 3: Antibacterial activity of extracts of *Bryophyllum. pinnatum* against selected MRSA isolates.

| Isolates | CONC (mg/ml) | Zone of inhibition (mm) | |
|----------|--------------|-------------------------|------------------|
| | | Aqueous fraction | Methanol extract |
| A5 | 100 | 23 | 13 |
| | 50 | 15 | 9 |
| | 25 | NZ | NZ |
| | 12.5 | NZ | NZ |
| | 6.25 | NZ | NZ |
| | 3.125 | NZ | NZ |
| B8 | 100 | 20 | 13 |
| | 50 | 18 | 9 |
| | 25 | 10 | 5 |
| | 12.5 | 9 | 3 |
| | 6.25 | 5 | 2 |
| | 3.125 | NZ | NZ |
| B10 | 100 | 26 | 16 |
| | 50 | 13 | 11 |
| | 25 | 9 | 7 |
| | 12.5 | 4 | 3 |
| | 6.25 | NZ | NZ |
| | 3.125 | NZ | NZ |
| B12 | 100 | 15 | 7 |
| | 50 | 13 | NZ |

| | | | | |
|--|-----|-------|----|----|
| | | 25 | NZ | NZ |
| | | 12.5 | NZ | NZ |
| | | 6.25 | NZ | NZ |
| | C4 | 3.125 | NZ | NZ |
| | | 100 | 10 | 8 |
| | | 50 | NZ | NZ |
| | | 25 | NZ | NZ |
| | | 12.5 | NZ | NZ |
| | | 6.25 | NZ | NZ |
| | C7 | 3.125 | NZ | NZ |
| | | 100 | 18 | 9 |
| | | 50 | 15 | 5 |
| | | 25 | 9 | 3 |
| | | 12.5 | NZ | NZ |
| | | 6.25 | NZ | NZ |
| | D16 | 3.125 | NZ | NZ |
| | | 100 | 12 | 7 |
| | | 50 | 9 | 3 |
| | | 25 | NZ | NZ |
| | | 12.5 | NZ | NZ |
| | | 6.25 | NZ | NZ |
| | | 3.125 | NZ | NZ |
| | E9 | 100 | 15 | 10 |
| | | 50 | 7 | 5 |
| | | 25 | NZ | NZ |
| | | 12.5 | NZ | NZ |
| | | 6.25 | NZ | NZ |
| | | 3.125 | NZ | NZ |

222 NZ= No Zone

223

224

225

226

227

228 Minimum Inhibitory Concentrations

229 The MIC and MBC of the methanol and aqueous fraction of the extracts against the test isolates
 230 are presented in Table 4. Results showed that the extract had MIC values lower than the MBC
 231 for all of the isolates hence showing its effect to be bacteriostatic.

232 Table 4: Minimum Inhibitory Concentration(MIC) and Minimum Bactericidal Concentration
 233 (MBC) of extracts against MRSA isolates

| Extracts | Isolates | MIC(mg/ml) | MBC(mg/ml) | 25 | 12.5 | 6.25 | 3.125 | 1.56 | 0.78 | 0.39 |
|------------------|----------|------------|------------|----|------|------|-------|------|------|------|
| | A5 | 12.5 | 25 | - | - | + | + | + | + | + |
| | B8 | 0.78 | 1.56 | - | - | - | - | - | - | + |
| Aqueous fraction | B10 | 0.78 | 1.56 | - | - | - | - | - | - | + |
| | B12 | ≥50 | ≥100 | + | + | + | + | + | + | + |
| | C4 | ≥50 | ≥100 | + | + | + | + | + | + | + |
| | C7 | ≥50 | ≥100 | + | + | + | + | + | + | + |
| | D16 | 6.25 | 12.5 | - | - | - | + | + | + | + |
| | E9 | 12.5 | 25 | - | - | + | + | + | + | + |
| | A5 | 25 | 50 | - | + | + | + | + | + | + |
| | B8 | 12.5 | 25 | - | - | + | + | + | + | + |
| Methanol extract | B10 | 6.25 | 12.5 | - | - | - | + | + | + | + |
| | B12 | 12.5 | 25 | - | - | + | + | + | + | + |
| | C4 | 25 | 50 | - | + | + | + | + | + | + |

| | | | | | | | | | |
|-----|------|----|---|---|---|---|---|---|---|
| C7 | 12.5 | 25 | - | - | + | + | + | + | + |
| D16 | 12.5 | 25 | - | - | + | + | + | + | + |
| E9 | 12.5 | 25 | - | - | + | + | + | + | + |

234

235 Key:

236 + = Growth

237 - = No Growth

UNDER PEER REVIEW

Rate of Kill

The results that show the relationship between the ability of certain concentrations of the test extracts to control the test organisms and contact time are shown in Tables 4 and 5. They further confirm the activity of the extract against the isolates, its bacteriostatic effect and time dependency.

Table 5a: Reduction pattern of MRSA isolates challenged with aqueous fraction of the methanolic extract of *Bryophyllum pinnatum* at MIC

| Time (min) | ISOLATES | | | | | | | | | | | | | | | |
|------------|---------------------|-------|-------|-------|---------------------|-------|-------|-------|---------------------|-------|-------|-------|---------------------|-------|-------|-------|
| | A5 | | | | B8 | | | | B10 | | | | B12 | | | |
| | A | B | C | D (%) | A | B | C | D (%) | A | B | C | D (%) | A | B | C | D (%) |
| 0 | 3.4×10 ⁴ | 4.531 | | | 7.3×10 ⁴ | 4.863 | | | 7.5×10 ⁴ | 4.875 | | | 3.6×10 ⁴ | 4.556 | | |
| 30 | 2.6×10 ⁴ | 4.415 | 0.116 | 2.56 | 6.2×10 ⁴ | 4.792 | 0.071 | 1.45 | 6.2×10 ⁴ | 4.793 | 0.082 | 1.68 | 3.1×10 ⁴ | 4.491 | 0.065 | 1.42 |
| 60 | 2.4×10 ⁴ | 4.380 | 0.151 | 3.33 | 5.5×10 ⁴ | 4.740 | 0.123 | 2.52 | 5.8×10 ⁴ | 4.763 | 0.112 | 2.29 | 2.6×10 ⁴ | 4.415 | 0.141 | 3.09 |
| 90 | 1.7×10 ⁴ | 4.230 | 0.301 | 6.64 | 4.4×10 ⁴ | 4.643 | 0.22 | 4.52 | 4.7×10 ⁴ | 4.672 | 0.203 | 4.16 | 1.7×10 ⁴ | 4.230 | 0.326 | 7.15 |
| 120 | 1.4×10 ⁴ | 4.146 | 0.385 | 8.49 | 3.6×10 ⁴ | 4.556 | 0.307 | 6.3 | 3.5×10 ⁴ | 4.544 | 0.331 | 6.7 | 1.3×10 ⁴ | 4.114 | 0.442 | 9.7 |
| 150 | 5.0×10 ³ | 3.699 | 0.832 | 18.36 | 2.6×10 ⁴ | 4.415 | 0.448 | 9.2 | 2.7×10 ⁴ | 4.431 | 0.444 | 9.1 | 6.0×10 ³ | 3.778 | 0.778 | 17.02 |

Key:

A= Cfu/ml

B= Log₁₀Cfu/ml

C= Log₁₀Cfu/ml reduction = Log₁₀ (Initial count) – Log₁₀ (count at time interval)

D = percentage reduction

Table 5b: Reduction pattern of MRSA isolates challenged with aqueous fraction of the methanolic extract of *Bryophyllum pinnatum* at MIC

| Time (min) | ISOLATES | | | | | | | | | | | | | | | |
|---------------|-------------------|-------|-------|-------|-------------------|-------|-------|-------|-------------------|-------|-------|-------|-------------------|-------|-------|-------|
| | C4 | | | | C7 | | | | D16 | | | | E9 | | | |
| | A | B | C | D (%) | A | B | C | D (%) | A | B | C | D (%) | A | B | C | D (%) |
| 0 | 3.1×10^4 | 4.491 | | | 3.2×10^4 | 4.505 | | | 5.9×10^4 | 4.771 | | | 5.6×10^4 | 4.748 | | |
| 30 | 2.5×10^4 | 4.398 | 0.093 | 2.07 | 2.5×10^4 | 4.398 | 0.107 | 2.37 | 5.6×10^4 | 4.748 | 0.023 | 0.48 | 4.7×10^4 | 4.672 | 0.076 | 1.6 |
| 60 | 1.8×10^4 | 4.255 | 0.236 | 5.25 | 1.6×10^4 | 4.204 | 0.301 | 6.68 | 3.9×10^4 | 4.591 | 0.18 | 3.77 | 3.4×10^4 | 4.531 | 0.217 | 4.57 |
| 90 | 8.0×10^3 | 3.903 | 0.588 | 13.09 | 1.5×10^4 | 4.176 | 0.329 | 7.30 | 3.3×10^4 | 4.519 | 0.252 | 5.28 | 2.5×10^4 | 4.398 | 0.35 | 7.37 |
| 120 | 6.0×10^3 | 3.778 | 0.713 | 15.87 | 6.0×10^3 | 3.778 | 0.727 | 16.13 | 2.2×10^4 | 4.342 | 0.429 | 8.99 | 1.6×10^4 | 4.204 | 0.544 | 11.45 |
| 150 | - | - | - | | 2.0×10^3 | 3.301 | 1.204 | 26.72 | 1.2×10^4 | 4.079 | 0.692 | 14.5 | 1.2×10^3 | 4.079 | 0.699 | 14.09 |

Key:

A= Cfu/ml

B= $\text{Log}_{10}\text{Cfu/ml}$

C= $\text{Log}_{10}\text{Cfu/ml}$ reduction = Log_{10} (Initial count) – Log_{10} (count at time interval)

D = percentage reduction

Table 6a: Reduction pattern of MRSA isolates challenged with aqueous fraction of the methanolic extract of Bryophyllum pinnatum at 2x MIC

| Time (min) | ISOLATES | | | | | | | | | | | | | | | |
|------------|---------------------|-------|-------|-------|---------------------|-------|-------|-------|---------------------|-------|-------|-------|-----|---|---|-------|
| | A5 | | | | B8 | | | | B10 | | | | B12 | | | |
| | A | B | C | D (%) | A | B | C | D (%) | A | B | C | D (%) | A | B | C | D (%) |
| 0 | 1.4×10 ⁴ | 4.146 | | | 6.2×10 ⁴ | 4.792 | | | 5.6×10 ⁴ | 4.748 | | | | | | |
| 30 | 1.1×10 ⁴ | 4.041 | 0.105 | 2.53 | 5.3×10 ⁴ | 4.724 | 0.068 | 1.41 | 4.6×10 ⁴ | 4.663 | 0.085 | 1.7 | | | | |
| 60 | 7.0×10 ³ | 3.845 | 0.301 | 7.26 | 3.5×10 ⁴ | 4.544 | 0.248 | 5.17 | 3.5×10 ⁴ | 4.544 | 0.204 | 4.29 | | | | |
| 90 | 5.0×10 ³ | 3.699 | 0.447 | 10.78 | 2.7×10 ⁴ | 4.431 | 0.361 | 7.53 | 2.8×10 ⁴ | 4.447 | 0.301 | 6.33 | | | | |
| 120 | 3.0×10 ³ | 3.477 | 0.669 | 16.85 | 1.6×10 ⁴ | 4.204 | 0.588 | 12.27 | 1.3×10 ⁴ | 4.114 | 0.634 | 13.35 | | | | |
| 150 | 1.0×10 ³ | 3.000 | 1.146 | 27.64 | 7.0×10 ³ | 3.845 | 0.947 | 19.76 | 8.0×10 ³ | 3.903 | 0.845 | 17.79 | | | | |

Key:

A= Cfu/ml

B= Log₁₀Cfu/ml

C= Log₁₀Cfu/ml reduction = Log₁₀ (Initial count) – Log₁₀ (count at time interval)

D = percentage reduction

Table 6b: Reduction pattern of MRSA isolates challenged with aqueous fraction of the methanolic extract of *Bryophyllum pinnatum* at 2x MIC

| Time (min) | ISOLATES | | | | | | | | | | | | | | | |
|------------|----------|---|---|-------|----|---|---|-------|---------------------|-------|-------|-------|---------------------|-------|-------|-------|
| | C4 | | | | C7 | | | | D16 | | | | E9 | | | |
| | A | B | C | D (%) | A | B | C | D (%) | A | B | C | D (%) | A | B | C | D (%) |
| 0 | - | - | - | - | - | - | - | - | 1.9×10 ⁴ | 4.279 | | | 1.4×10 ⁴ | 4.146 | | |
| 30 | - | - | - | - | - | - | - | - | 1.7×10 ⁴ | 4.230 | 0.085 | 1.98 | 1.0×10 ⁴ | 4.000 | 0.146 | 3.52 |
| 60 | - | - | - | - | - | - | - | - | 1.2×10 ⁴ | 4.079 | 0.204 | 4.76 | 5.0×10 ⁴ | 3.699 | 0.447 | 10.78 |
| 90 | - | - | - | - | - | - | - | - | 1.0×10 ⁴ | 4.000 | 0.301 | 7.03 | 2.0×10 ⁴ | 3.301 | 0.845 | 20.38 |
| 120 | - | - | - | - | - | - | - | - | 5.0×10 ³ | 3.699 | 0.634 | 14.81 | 1.0×10 ⁴ | 3.000 | 1.146 | 27.64 |
| 150 | - | - | - | - | - | - | - | - | 3.0×10 ³ | 3.477 | 0.845 | 19.74 | - | - | - | - |

Key:

A= Cfu/ml

B= Log₁₀Cfu/ml

C= Log₁₀Cfu/ml reduction = Log₁₀ (Initial count) – Log₁₀ (count at time interval)

D = percentage reduction

Discussion

Recently, there has been a surge in the report of antibiotic resistant strains of clinically important pathogens. Among the Gram Positive organisms, a pandemic of resistant *Staphylococcus aureus* known as Methicillin resistant *Staphylococcus aureus* (MRSA) currently poses a threat [17]. MRSA, a very important strain of *S.aureus* was first reported in 1961, since then, MRSA infection is increasingly prevailing and continues to pose serious therapeutic challenge. Methicillin acts through competitive inhibition of transpeptidase enzyme by its affinity to penicillin-binding protein 2 (PBP2) used by bacteria to cross-link the peptide (D-alanyl-alanine) mandatory for peptidoglycan synthesis. It was developed to treat staphylococcal infections. Resistance to methicillin is developed due to acquisition of penicillin-binding protein 2A(PBP2A) encoded by the *mecA* gene from a mobile staphylococcal cassette chromosome (SCC). The current diagnosis for MRSA is basically resistance to either oxacillin or ceftiofuran, which indicates non-susceptibility to all other groups of β -lactams. Most MRSA strains are known to be resistant to multiple classes of antibiotics and therefore, cannot be treated with the conventional B-lactams [18]. The search for the development of novel agents against MRSA has continued and the results presented here are part of our effort to establish the candidacy of *Byophyllum pinnatum* in the formulation of agents that can be used to treat infections due to MRSA.

Results obtained showed that 89(59%) of the 150 urine samples analysed were positive for *Staphylococcus aureus* while 66(74%) of the *S. aureus* isolates were resistant to the ceftiofuran (30 μ g) and were considered MRSA [11]. This shows a high prevalence of MRSA and compares to the work of [19] who reported a prevalence rate of 70% in patients attending clinic in University of Benin Teaching Hospital and [20] who reported a prevalence rate of 75% from the wounds of hospitalised patients of Ahmadu Bello University Teaching Hospital also in Nigeria.

Phytochemical screening confirmed the presence of those secondary metabolites which are known to be responsible for antimicrobial activity namely tannins and flavonoids. Tannins are known to cause death of organisms by depriving them of iron and also forming complexes with polysaccharides while flavonoids form complexes with bacterial cell walls [21]. The presence of these metabolites has been linked to the antibacterial activity of plants [22].

Though the detection of the *Mec A* gene is generally accepted as the gold standard for the detection of MRSA, the ceftiofuran (30 μ g) disc diffusion test has been reported to be in concordance with the detection of *Mec A* gene by PCR. It is therefore widely accepted as a genuine method for the detection of MRSA [23]). This method was used in this work for the identification of MRSA. The PCR assay technique for *Mec A* gene detection was however used in further confirmation of MRSA species of a few isolates which were particularly interesting as they showed resistance to a wide range of antibiotics than others. Results obtained confirm that 7 out of 8 isolates tested were *Mec A* gene positive (Figure 1). This appears good enough to

confirm that the PCR assay technique and the disc diffusion test are comparable since we did not have the capacity to run all the samples identified by the disc diffusion method.

How useful a plant product will be in the formulation of a medicament will be determined to a great extent by its toxicity. Any extract whose LD₅₀ is greater than 500mg/kg is considered not toxic [24]. Result obtained shows the LD₅₀ of our extract is 866.03 (Table 2) confirming it only moderately toxic.

Susceptibility results obtained confirmed the potential of the plant extract in inhibiting the organisms used in the study (Table 3). The aqueous fraction showed a relatively better activity possibly because the active metabolites identified which are known to be polar must have been concentrated into the aqueous fraction since water which is polar will attract polar compounds. The results showed the activity of the extract to be concentration dependent. It is clear that the purer the extract is, the better the activity will be. The result of isolate C4 seems to be of interest. It is one of the original 66 isolates confirmed to be cefoxitin (30µg) resistant hence considered an MRSA. The PCR assay however showed it to be Mec A gene negative (Fig 1). When susceptibility tests were done, it showed very poor susceptibility and high MIC with the concentration of the extract employed. This points to a higher resistant state compared to the other isolates which were Mec A gene positive and confirmed MRSA by the golden rule. Is it possible that the resistance in this isolate is due to a possible alternative genetic possibility other than Mec A gene acquisition?

The result of the rate of kill of the test fraction is shown in Tables 5 and 6. It can be observed that the extract exhibited some reduction in the viable cell count of the 8 MRSA isolates tested. The results showed a reduction in viable cells of between 0.44Log₁₀cfu/ml and 1.20Log₁₀ cfu/ml which represents a percentage reduction of between 9.1 and 26.72 after 150 minutes of contact with the isolates. Initially, after 30 minutes of interaction, the reduction in viable cell count was only between 0.023Log₁₀ cfu/ml and 0.116Log₁₀ cfu/ml representing a percentage reduction of between 0.48 and 2.56. This confirms the activity of the test fraction to be time dependent since its effectiveness in reducing the number of viable cell is better after longer time of contact with the cells. At 2×MIC, results of rate of kill obtained showed that the reduction in viable cells after 30 minutes of interaction was between 0.068Log₁₀cfu/ml and 0.146Log₁₀cfu/ml representing a percentage reduction of 1.41% and 3.52% while after 120 minutes it was between 0.588Log₁₀cfu/ml (12.27%) and 1.146Log₁₀cfu/ml (27.64%) confirming that the activity of the test fraction is also concentration dependent when compared with the result obtained using the MIC. For time- kill endpoint determinations, bacteriostatic activity is a reduction of between 0 and 3 Log₁₀ cfu/ml while bactericidal activity is a reduction of 3 Log₁₀ cfu/ml and above at different time intervals (30,60,90,120,150) from the original population at 0 minutes [25]. Results of the time-kill assay obtained, therefore confirms a bacteriostatic activity at the MIC and 2×MIC concentrations used in the study. It is not impossible that at higher concentration of extract like 4xMIC, 8xMIC, 16xMIC a bacteriocidal effect can be obtained but this was not studied.

CONCLUSION

As the menace of bacterial resistance continues to pose serious problems and the search for alternative anti-MRSA agents from natural sources continues, results obtained in this study showed that *Bryophyllum pinnatum* will be a possible candidate for further investigation for use in the formulation of new anti-MRSA agent.

REFERENCES

1. Cole, A. M., Tahks, O. A., Yoshioka. D., Kim, Y. H., Park, A. and Ganz, T. Determinants of *Staphylococcus aureus* nasal carriage. *Clin Diag Lab Immunol.* 2001;8 (6):1064-
2. Hoffman, Barbara). Williams gynecology, 2nd edition. New York. McGraw-Hill Medic.2012
- 3 .Kitara, M. D., Antwar, A. D., Acullu, E., Odongo-Aginya, E. Aloyo, J. and Fendu, M. Antibiotic susceptibility of *Staphylococcus aureus* in suppurative lesions in Lacor hospital Uganda. *Afr Health Sci.*; 11 suppl(1):S34-S39.
4. Malachowa, N. and Deleo, F. R. Mobile genetic elements of *Staphylococcus aureus*. *Cell Mol. Life Sci*2010.; 67(18):3057-71.
- 5 Mazhar, S. A., Ibrahim, A. A., Emad, H., Alla, A. J. and Salih, K. Antimicrobial susceptibility pattern of *Staphylococcus aureus* isolated from clinical specimens in Northern area of Jordan. *Iran J Microbiol.*201 .7(5):265-272.
- 6 Mcphee, S. J., Papadakis, M. A. and Rabow, M. W. Current Medical Diagnosis and Treatment. *McGraw-Hill Medical.* 2012;1232-1235.
7. Sachin, K. and Seema, B. Increasing trend of methicillin resistant *Staphylococcus aureus* in Jaipur, Rajasthan, India. *African Journal of Microbiology Research.*2016; 10(34) 1417-1421.
8. Rahimi, F., Katouli, M. and Pourshafie, M. R. (2014). Characteristics of hospital and community-acquired methicillin resistant *Staphylococcus aureus* in Tehran, Iran. *J. Med. Microbiol*; 63(pt6):796-804.
9. Ali, E. A.The chemical constituents pharmacological effects of *B. calycinum*. A review. *International Journal of Pharma Sciences and Research.*2013; 4(12):171-176.
10. Cheesbrough, Monica. *District Laboratory Practice in Tropical Countries.* Part II. United Kingdom: Cambridge University Press 2000
11. Clinical Laboratory Standard Institute (CLSI).Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fourth Informational Supplement. Clinical Laboratory Standards Institute, Wayne, PA. 2014; Vol. 30 (1).
12. Sofowora, (1993). Medicinal plants and traditional medicines in Africa. New York: John Wiley and Sons. 119.
13. Trease, G. E. and Evans, W. C. (1989). *Pharmacognosy.* 15th edn. Brailliar Tridel c an, Macmillan Publishers.
14. Udobi, C. E. and Onaolopo, J. A. (2009). Phytochemical analysis and antibacterial evaluation of the leaf, Stem bark and root of African locust bean (*Parkia biglobosa*). *Journal of Medicinal Plants Research.*2009; 3(5), pp. 338-344.

15. Lorke, D. (1983). A new approach to practical acute toxicity testing. *Archives of Toxicology*.1983; 54, 275–287. <http://dx.doi.org/10.1007/BF01234480>
16. Sahm DF, Washington JA . Antibacterial susceptibility test dilution methods: In: Manual of clinical Microbiology. Lennette E.H. 5th ed Am. Soc. Microbiol. 1990; Washington DC, 1105-1116.
17. Rossolini, G. M., Arena, F., Pecile, P. and Pollini, S. (2014). Update on the antibiotic resistance crisis. *Clin Opin. Pharmacol.* 2014;18:56-60.
18. Dayan Fredalin Basri, Lee Wee Xian, Nur Indah, Abdul Shukar and Jalifa Latip. Bacteriostatic antimicrobial combination:Antagonistic interaction between Epsilon-viniferin and vancomycin against Methicillin resistant *Staphylococcus aureus*. *Biomed Research International*. 2014; article Id 461756
19. Onemu O.S and Ophori, E.A.Prevalence of *S. Aureus* in clinical specimens obtained from patients attending the University of Benin Teaching Hospital, Benin City, Nigeria. *J. Nat Sci. Res.* 2013; 3(5), 154-159
20. Udobi, C.E; Obajuluwa, A. F and Onaolapo, J. A. Prevalence and antibiotic resistance pattern of methicillin resistant *Staphylococcus aureus* infection from an orthopaedic hospital in Nigeria. *Biomed Res. Journ.* 2013 I D 860467.
21. Salbart, A (1991). Antimicrobial properties of Tannins. *Phytochemistry*, 30: 3875-3883 in Jaipur, Rajasthan, India. *African Journal of Microbiology Research*.1991; 10(34) pp1417-1421.
22. Lewis, K. and Ausubel, F. M. Prospects for plant derived antibacterials. *Nat. Biotechnol.*2006; 24(12):1504-1507
23. Uzun B, Karataş Şener AG, Güngör S, Afşar I, Yüksel Ergin O, Demirci M. [Comparison of Cefoxitin Disk Diffusion Test, Automated System and Chromogenic Medium for Detection of Methicillin Resistance in *Staphylococcus aureus* Isolates]. *Mikrobiyol Bul.*2013; 47(1):11-18.
24. Ngulde, S. I., Tijjani, M. B., Ihopo, J. M., & Ya'uba, A. M. Anti-trypanosomal potency of methanol extract of *Cassia arereh* Delile root bark in albino rats. *International Journal of Drug Research and Technology*2013; 3(1), 1–7.
25. Drago L, De Vecchi E, Lombardi A, Nicola L, Valli M, Gismondo MR, *et al.* Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against *Bacillus anthracis* clinical isolates. *J Antimicrob Chemother* 2002;50:1059-63.